In familiar AD, increased levels of NF-L were detected in mutation carriers than in non-carriers, and there was an increase in annual rate in mutation carriers as early as 16 years before the estimated symptom onset, demonstrating their potential role as a biomarker of phenoconversion [28,29]. The gene discussed is NEFL; the disease is Alzheimer disease.